Aztreonam plus avibactam for serious gram-negative infections
Treatments studied
Part of Infections clinical trials.
This trial compares two IV antibiotics (aztreonam and avibactam) against the best available treatment for serious gram-negative infections. It may help people who are hospitalized and need IV antibiotics, especially when the infection is caused by certain gram-negative bacteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age is 9 months up to under 18 years
- You have a suspected or confirmed serious gram-negative infection (such as belly/abdominal, bladder/urine, lung in hospital, or bloodstream infection)
- You need to be in the hospital and receive IV antibiotics
- Your infection bacteria are expected to respond to aztreonam plus avibactam for up to 14 days
- You are not pregnant, not breastfeeding, and you can use reliable birth control if you could get pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well an antibiotic called ceftazidime-avibactam (CAZ-AVI) works in people with blood cancers or those who have had a stem cell transplant. It aims to find the right dose and see if the bacteria become resistant.
This study tests a new antibiotic called aztreonam-avibactam (ATM-AVI) for treating serious bacterial infections in hospitalized babies under 9 months old. The goal is to see if it's safe and works well.
This trial is checking how well a combination of two antibiotics, aztreonam and avibactam, works in patients who have a specific type of drug-resistant bacterial infection in the belly or lungs. It aims to offer a new treatment option for infections that are hard to cure.
This trial studies a combination antibiotic called aztreonam-avibactam for treating infections caused by hard-to-treat bacteria, especially those that produce certain enzymes (MBLs). It aims to see how well this medicine works in hospital patients.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
Hear when a new Gram-Negative Bacterial Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.